Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer

Cancer

Volumn 110, Issue 7, 2007, Pages 1478-1484

  Halabi, Susan ^a,b,e   Ou, San San ^b   Vogelzang, Nicholas J ^c   Small, Eric J ^d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CALGB Statistical Center   (United States)

^c NEVADA CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Castration recurrent prostate cancer; Clinical outcomes; Obesity; Race

Indexed keywords

ALKALINE PHOSPHATASE; GONADORELIN AGONIST; LACTATE DEHYDROGENASE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DISEASE SEVERITY; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OBESITY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTECTION; RECURRENT CANCER;

AFRICAN AMERICANS; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BODY MASS INDEX; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OBESITY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEVERITY OF ILLNESS INDEX; TESTOSTERONE; UNITED STATES;

EID: 34648825008     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22932     Document Type: Article

References (35)

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among U.S. adults, 1999-2000. J Am Med Dir Assoc. 2002;288:1723-1727.
2. Criqui MH, Mebane I, Wallace RB, et al. Multivariate correlates of adult blood pressures in nine North American populations: The Lipid Research Clinics Prevalence Study. Prev Med. 1982;11:391-402.
3. Hubert HB, Freinleib M, McNamra PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67:968-977.
4. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes and obesity related health risk factors. JAMA 2003;289:76-79.
5. Presti JC, Jr, Lee U, Brooks JD, et al. Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol. 2004;171:2199-2202.
6. Amling CL, Kane CJ, Riffenburgh RH, et al. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001;58:723-728.
7. Strom SS, Wang X, Pettaway CA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11:6889-6894.
8. Kane CJ, Bassett WW, Sadetsky N, et al. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005;173:732-736.
9. Freedland SJ, Grubb KA, Yiu SK, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174:919-922.
10. Freedland SJ, Terris MK, Presti JC Jr, et al. Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins. J Urol. 2004;172:520-524.
11. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
12. Bassett WW, Cooperberg MR, Sadetsky N, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005;66:1060-1065.
13. Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol. 2004;22:446-453.
14. Freedland SJ, Platz EA, Presti JC, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175:500-504.
15. Strom SS, Kamat AM, Gruschkus SK, et al. Influence of obesity on biochemical and clinical failure after external-bean radiotherapy for localized prostate cancer. Cancer. 2006;107:631-639.
16. Merrick GS, Butler WM, Wallner KE, et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology. 2005;65:95-100.
17. Halabi S, Small EJ, Vogelzang NJ. An elevated body mass index predicts for longer overall survival duration in men with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol. 2005;23:2434-2435.
18. Farkas A, Marcella S, Rhoads GG. Ethnic and racial differences in prostate cancer incidence and mortality. Ethn Dis. 2000,10:69-75.
19. Mettlin CJ, Murphy GP. Why is the prostate cancer death rate declining in the United States? Cancer 1998;82:249-251.
20. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: recommendations from the PSA working group. J Clin Oncol. 1999;17:3461-3467.
21. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239.
23. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232-1237.
24. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972-3982.
25. Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10:345-353.
26. Calle EE, Rodrigues C, Walker-Thurmond K, et al. Overweight, obesity and mortality from cancer in a prospectively studies cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
27. Flanagan JR, Carney-Doebbeling C, Jones L, et al. Metabolic syndrome predicts for shorter response to hormonal therapy in prostate cancer. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24(18Suppl).
28. Platz EA, Leitzmann MF, Michaud DS, et al. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res. 2003;63:8542-8548.
29. Chan JM, Stamfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor 1 in relation to prostate cancer risk: a prospective study. Science. 1998;279:563-566.
30. Pummer K, Stettner H, Trummer H, et al. Body mass is an independent predictor for organ confined prostate cancer. J Urol. 2000;163:183(Suppl Abstract 809).
31. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001;47:52-57.
32. Massengill JC, Sun L, Moul JW, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003;169:1670-1675.
33. Frystyk J, Vestbo E, Skjaerbaek C, et al. Free insulin-like growth factors in human obesity. Metabolism. 1995;44:37-44.
34. Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urology. 2005;65:433-439.
35. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006;340:1158-1166.